Back to Search
Start Over
Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis
- Source :
- Journal of medical economics. 23(6)
- Publication Year :
- 2020
-
Abstract
- Background: The fixed-dose combination foam formulation of calcipotriene 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) has demonstrated efficacy and a favorable safety profile for the treatment of plaque psoriasis. Recently, a topical lotion of the combination of halobetasol 0.01% plus tazarotene 0.045% (HP/TAZ) was approved for treating adult plaque psoriasis. Currently, no head-to-head studies have compared Cal/BD foam with HP/TAZ lotion. Objective: Compare the effectiveness and drug incremental cost per responder (ICPR) of Cal/BD foam vs. HP/TAZ lotion in moderate-to-severe plaque psoriasis. Methods: An anchor-based, matching-adjusted indirect comparison was conducted for PGA treatment success (Physician’s Global Assessment of “clear” or “almost clear,” [PGA 0/1] with at least a 2-point improvement) using individual patient data from 3 randomized clinical studies of Cal/BD foam and published data from 2 randomized, Phase 3 clinical studies of HP/TAZ lotion. The number needed to treat and ICPR were also calculated. Results: After reweighting of patients in the Cal/BD foam studies to match summary baseline characteristics of the HP/TAZ lotion study patients and anchoring to vehicle effect, 4 weeks of Cal/BD foam produced a significantly greater rate of treatment success than 8 weeks of HP/TAZ lotion treatment (51.4 vs. 30.7%; treatment difference = 20.7%, p Conclusions: The indirect comparison analyses showed that Cal/BD foam was associated with a greater rate of treatment success, lower ICPR, and quicker treatment response than HP/TAZ lotion in adult patients with moderate-to-severe plaque psoriasis.
- Subjects :
- Adult
medicine.medical_specialty
Halobetasol
Betamethasone dipropionate
Administration, Cutaneous
Betamethasone
Severity of Illness Index
Tazarotene
Calcitriol
Psoriasis
Medicine
Humans
Multicenter Studies as Topic
Aged
Randomized Controlled Trials as Topic
Plaque psoriasis
Clobetasol
business.industry
Health Policy
Nicotinic Acids
Middle Aged
medicine.disease
Dermatology
Safety profile
Drug Combinations
Lotion
Calcipotriene
lipids (amino acids, peptides, and proteins)
Dermatologic Agents
business
medicine.drug
Subjects
Details
- ISSN :
- 1941837X
- Volume :
- 23
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Journal of medical economics
- Accession number :
- edsair.doi.dedup.....d4f34f2f4b57ddfb9339b78552d626fd